uniQure Announces Pricing of Upsized $225 Million Public Offering
Rhea-AI Summary
uniQure (Nasdaq:QURE) priced an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, targeting approximately $225 million in gross proceeds before fees.
The company granted underwriters a 30-day option for up to 741,758 additional shares, with closing expected on or about June 25, 2026, subject to customary conditions.
Positive
- Upsized equity offering targeting approximately $225 million in gross proceeds
- Flexible 30-day underwriter option for up to 741,758 additional shares
- Access to capital via effective shelf registration on Form S-3
Negative
- New share issuance may dilute existing uniQure shareholders
- Net proceeds will be reduced by underwriting discounts and offering expenses
News Market Reaction – QURE
In the Jun 24 session, QURE declined 0.39%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 29 | Offering closing | Negative | -1.7% | Closed upsized equity offering with ~$345M gross proceeds including greenshoe. |
| Sep 25 | Offering pricing | Negative | +3.1% | Priced upsized $300M equity deal with shares and pre-funded warrants. |
| Sep 24 | Offering launch | Negative | +10.8% | Announced proposed $200M equity and pre-funded warrant offering. |
| Jan 08 | Offering pricing | Negative | -9.8% | Priced public equity offering of ~4.4M shares for ~$75M gross proceeds. |
| Jan 07 | Offering launch | Negative | -9.8% | Announced launch of underwritten equity and pre-funded warrant offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related headlines have produced mixed but often volatile reactions, with a slightly negative average move and both sharp gains and selloffs.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
bookrunning managers financial
rule 10b5-1 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of
Leerink Partners, Stifel, Guggenheim Securities and RBC Capital Markets are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on June 22, 2026 and a final prospectus supplement and the accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at +1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089 or by email at equityprospectus@rbccm.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our expectations of market conditions, the satisfaction of customary closing conditions and the timing of the public offering, the gross proceeds we expect to receive and other statements identified by words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" and similar words or expressions.
Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering, continued interest in our rare disease and gene therapy portfolio, the ability to develop our product candidates and technologies, regulatory developments, the impact of changes in the financial markets and global economic conditions, and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on March 2, 2026, our Quarterly Report on Form 10-Q filed on May 5, 2026, the preliminary prospectus supplement filed with the SEC on June 22, 2026 and the accompanying prospectus, and other filings that uniQure makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
uniQure Contacts
| For Investors: | For Media: | |
| Chiara Russo | Tom Malone | |
| Direct: 781-491-4371 | Direct: 339-970-7758 | |
| Mobile: 617-306-9137 | Mobile: 339-223-8541 | |
| c.russo@uniQure.com | t.malone@uniQure.com |
